IFNA17 and renal cell carcinoma: Sunitinib has been approved as first-line agents for the treatment of advanced RCC; it is an oral multi-targeted inhibitor (TKI) with higher response rates and significant improvement in median PFS compared to patients receiving IFN-α and with a significantly superior overall response rate (ORR) compared to placebo subgroup.